Furthermore, targeting S1PR3 with the inhibitor TY-52156 reduced tumour burden and prolonged survival in T-ALL patient-derived xenografts in mice [71], suggesting S1PR3 may be a therapeutic target in this CSC-driven disease [72]. This evidence concerns the gene S1PR3 and acute lymphoblastic leukemia.